证券代码：600200 证券简称：江苏吴中 公告编号：临2025-020 江苏吴中医药发展股份有限公司 股票交易异常波动的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 江苏吴中医药发展股份有限公司（以下简称"公司"）于 2025 年 4 月 24 日、4 月 25 日、4 月 28 日股票交易连续三个交易日内收盘价格跌幅偏离值累 计超过 20%，根据《上海证券交易所交易规则》的有关规定，属于股票交易异常 波动的情形。 公司被立案调查，存在重大违法强制退市风险。公司已被中国证券监督 管理委员会(以下简称"中国证监会")立案调查，若后续经中国证监会行政处罚 认定的事实，触及《上海证券交易所股票上市规则》规定的重大违法强制退市情 形，即使公司 2024 年实现盈利，公司股票也将被实施重大违法强制退市。 公司 2024 年度财务报告不排除被出具无法表示意见的审计报告。目前， 公司正积极与审计机构保持沟通并补充材料，努力配合审计机构审计工作，尽最 大努力消除影响审计意见类型的风险事项，最终审计意见类型须以审计机构正式 出具的审计 ...

(签字页见下) (本页无正文,为致江苏吴中医药发展股份有限公司的回复函的签字页) 实际控制人: 致江苏吴中医药发展股份有限公司的回复函 江苏吴中医药发展股份有限公司: 你公司函悉。经核查,截至目前,除已披露信息外,不存在影响上市公司 股票交易价格异常波动的重大信息,不存在应披露而未披露的重大信息,包括 但不限于重大资产重组、股份发行、收购、债务重组、业务重组、资产剥离、 资产注入、股份回购、股权激励、破产重整、重大业务合作、引进战略投资者 等重大事项。 特此回复。 2025 年 4 月 28 日 钱群英 ...

苏州吴中 你公司函悉。经我公司核查,截至目前,除已披露信息外,不存在影响上 市公司股票交易价格异常波动的重大信息，不存在应披露而未披露的重大信息, 包括但不限于重大资产重组、股份发行、收购、债务重组、业务重组、资产剥 离、资产注入、股份回购、股权激励、破产重整、重大业务合作、引进战略投 资者等重大事项。 特此回复。 致江苏吴中医药发展股份有限公司的回复函 江苏吴中医药发展股份有限公司: ...

Core Viewpoint - Jiangsu Wuzhong has faced significant challenges due to allegations of information disclosure violations and financial irregularities, leading to a sharp decline in stock price and potential risks of forced delisting, despite recent profitability in its aesthetic medicine segment [1][3][12]. Financial Performance - Jiangsu Wuzhong reported revenues of 2.026 billion yuan and 2.240 billion yuan for 2022 and 2023, respectively, with net losses of 76.27 million yuan and 71.95 million yuan [1]. - The company forecasts a turnaround in 2024, expecting a net profit of 55 million to 80 million yuan, driven by its aesthetic medicine product AestheFill [1][12]. Aesthetic Medicine Segment - Since 2021, Jiangsu Wuzhong has intensified its focus on the aesthetic medicine sector, which has become a key growth driver [2][11]. - AestheFill, launched in April 2024, is projected to significantly contribute to revenue, with expectations of generating approximately 350 million yuan in 2024 [12][13]. Regulatory and Legal Issues - The company has been under investigation by the China Securities Regulatory Commission (CSRC) for alleged information disclosure violations since February 2023, which has led to a stock price drop of over 50% [3][5]. - Jiangsu Wuzhong's subsidiary is facing criminal charges related to tax fraud, further complicating the company's legal landscape [6][7]. Financial Health Concerns - The company has exhibited a "high debt, high cash" situation, with cash holdings of 1.713 billion yuan and total borrowings of 1.71 billion yuan, raising concerns about financial management [3][4]. - As of the end of 2024, the company reported cash reserves of 1.412 billion yuan, indicating ongoing financial strain [4]. Market Outlook - The aesthetic medicine market in China is expected to grow rapidly, with projections indicating a market size of 11.52 billion yuan by 2027, driven by a compound annual growth rate of 54.73% from 2021 to 2025 [13]. - Despite the competitive landscape, Jiangsu Wuzhong's strategic investments in aesthetic medicine may position it for future growth, contingent on resolving current legal and regulatory challenges [12][13].

A股三大指数早盘集体上涨，截至午盘，沪指涨0.15%，深证成指涨0.87%，创业板指涨1.07%，北证50 指数涨1.11%。全市场半日成交额7331亿元，较上日同期缩量469亿元。全市场超3800只个股上涨。 盘面上，房地产板块早盘走高， 大龙地产3分钟内直线涨停 。电力板块延续活跃，华银电力封板。 光模块、铜缆高速连接等AI硬件方向亦表现强势，仕佳光子、致尚科技涨超10%。创新药板块早盘 局部调整，江苏吴中跌停。 港股方面，恒生指数和恒生科技指数均高开高走，截至午间收盘，恒指涨1.36%，恒生科技指数涨 1.87%，国企指数涨1.29%。地产股集体走高，金辉控股盘中最高涨超80%。 地产板块再度走强 大龙地产直线涨停 地产板块25日盘中再度走强。截至午间收盘，A股南国置业、世联行、渝开发、大龙地产纷纷涨停。 大 龙地产自9时56分起直线拉升，3分钟内封住涨停。 港股市场，金辉控股盘中一度涨超80%，截至发稿涨超43%。融信中国涨超17%，远洋集团涨超11%， 中梁控股、龙湖集团等跟涨。 | | 09993 金辉控股 | | | 3.230 | +0.980 | | --- | --- | --- | -- ...

化学制药板块盘初走低，江苏吴中（600200）跌停，天新药业（603235）逼近跌停，苑东生物、华纳药 厂、立方制药（003020）跌幅居前。 ...

| 买/ 卖 | 会员营业部名称 | 买入金额（万元） | 卖出金额（万元） | | --- | --- | --- | --- | | 买一 | 沪股通专用 | 1259.52 | | | 买二 | 东方财富证券股份有限公司拉萨东环路第一证券营业 部 | 295.90 | | | 买三 | 东方财富证券股份有限公司拉萨东环路第二证券营业 部 | 250.48 | | | 买四 | 中国银河证券股份有限公司大连人民路证券营业部 | 250.19 | | | 买五 | 国泰海通证券股份有限公司总部 | 245.51 | | | 卖一 | 沪股通专用 | | 1793.34 | | 卖二 | 国泰海通证券股份有限公司总部 | | 567.31 | | 卖三 | 国泰海通证券股份有限公司上海福山路证券营业部 | | 466.21 | | 卖四 | 西部证券股份有限公司上海世纪大道证券营业部 | 455.43 | | --- | --- | --- | | 卖五 | 东亚前海证券有限责任公司上海分公司 | 441.03 | 江苏吴中(600200)今日跌停，全天换手率9.45%，成交额2.97亿元，振幅3.64%。龙 ...

因涉嫌信息披露违法违规，被中国证监会立案后，存在退市风险的江苏吴中（600200）医药发展股份有 限公司(以下简称"江苏吴中")又遇新麻烦，因贸易业务部分应收账款及应收票据逾期未收回、子公司骗 取出口退税等多种原因，其2024年报不排除被审计机构出具无法表示意见的审计报告。截至4月24日收 盘，江苏吴中报4.39元/股，下跌10.04%，市值31.26亿元，距2月26日被立案时，股价已"腰斩"。 经历多次跨界转型，刚靠"童颜针"艾塑菲等医美业务实现业绩翻身，短短数月却又陷入退市危机，江苏 吴中经历了什么？ 年报或被出具无法表示意见的审计报告 4月23日晚，江苏吴中第8次发布立案调查进展，公司已被中国证监会立案调查，截至目前，中国证监会 的调查尚在进行中，公司尚未收到就上述立案调查事项的结论性意见或决定。若后续经中国证监会行政 处罚认定的事实，触及《上海证券交易所股票上市规则》规定的重大违法强制退市情形，即使公司2024 年实现盈利，公司股票也将被实施重大违法强制退市。 江苏吴中还在公告中披露，公司2024年度财务报告不排除被出具无法表示意见的审计报告，公司股票可 能被上海证券交易所实施退市风险警示。 2022 ...

Market Performance - On April 23, 2025, A-shares showed mixed results with the Shanghai Composite Index down 0.1% at 3296.36 points, while the Shenzhen Component Index rose 0.67% to 9935.8 points and the ChiNext Index increased by 1.08% to 1949.16 points. The total trading volume in the Shanghai and Shenzhen markets was 12,297 billion yuan, an increase of 1,397 billion yuan from the previous trading day [1] - Hong Kong stocks collectively rose, with the Hang Seng Index up 2.37% or 510.30 points, closing at 22,072.62 points, and the Hang Seng Technology Index increasing by 3.07% to 5049.4 points. The total trading volume was 2,606.19 billion HKD [1] - U.S. stock indices also saw gains, with the Dow Jones up 1.07% at 39,606.57 points, the Nasdaq rising 2.50% to 16,708.05 points, and the S&P 500 increasing by 1.67% to 5,375.85 points [1] New Stock Listings - Jiangshun Technology, with a stock code of 001400, was listed at an issuance price of 37.36 billion yuan and a price-to-earnings ratio of 15.32 times. The company specializes in the research, design, production, and sales of aluminum profile extrusion molds and related equipment [3] - Tianyouwei, with a stock code of 603202, was listed at a price of 93.5 yuan per share and a price-to-earnings ratio of 13.5 times. The company focuses on the research, design, production, and sales of automotive instruments and is expanding into the smart cockpit sector [3] Industry Developments - The Greater Bay Area (Dongguan) Artificial Intelligence Alliance was established on April 23, 2025, led by Huawei, OPPO, and vivo, along with 18 other significant entities. The alliance aims to utilize over 10,000P of intelligent computing power by 2027 and develop over 100 AI+ advanced manufacturing demonstration applications [4] - In the first quarter of 2025, the average rent for residential properties in 50 cities in China decreased by 0.44%. The average rent was 35.3 yuan per square meter per month in March, reflecting a year-on-year decline of 3.40% [4] Regulatory Actions - The European Union imposed its first fines under the Digital Markets Act, totaling 700 million euros (approximately 798 million USD) against Apple and Meta for antitrust violations. Apple was fined 500 million euros, while Meta received a 200 million euro fine [5]

Core Viewpoint - Jiangsu Wuzhong Pharmaceutical Development Co., Ltd. is under investigation by the China Securities Regulatory Commission (CSRC) for suspected violations of information disclosure laws, which may lead to significant risks of forced delisting, even if the company achieves profitability in 2024 [2][3]. Group 1: Investigation and Delisting Risks - The company has been officially notified of the investigation by the CSRC due to suspected violations of securities laws, and the investigation is ongoing [3]. - If the CSRC's findings result in a determination of major violations as per the Shanghai Stock Exchange listing rules, the company's stock may face forced delisting regardless of its financial performance in 2024 [2][3]. Group 2: Audit Report Concerns - There is a possibility that the annual financial report for 2024 may receive an audit report with a disclaimer of opinion due to several factors, including overdue receivables and ongoing legal issues involving a subsidiary [4]. - The company is actively communicating with its auditing firm to mitigate risks that could affect the audit opinion [4]. Group 3: Legal and Financial Issues - The company's wholly-owned subsidiary is facing criminal charges related to export tax fraud, which could impact the company's operations and financial standing [5]. - Some bank accounts of the company and its subsidiary have been frozen due to overdue loans, which may further affect the company's financing capabilities [5].